Loading...
•
Sep 30, 2025
IRadimed Q3 2025 Earnings Report
IRadimed posted record revenue and earnings in Q3 2025, supported by strong demand across product lines and a successful transition to its new Orlando facility.
Key Takeaways
IRadimed reported its seventeenth consecutive quarter of record revenue, reaching $21.2 million in Q3 2025. The company delivered GAAP EPS of $0.43 and non-GAAP EPS of $0.47, maintaining a strong 78% gross margin despite operational transitions. Full-year guidance was raised, reflecting robust demand and expectations for continued momentum.
Record quarterly revenue of $21.2 million, up 16% year-over-year
Net income rose to $5.58 million with GAAP EPS of $0.43
Gross margin remained strong at 78% during operational transition
Raised full-year revenue and EPS guidance amid strong backlog
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
IRadimed expects continued growth in Q4 2025, driven by strong product demand and early shipments of its next-generation IV pump.
Positive Outlook
- Q4 2025 revenue forecasted between $21.4M and $22.4M
- Q4 GAAP EPS expected between $0.43 and $0.47
- Q4 non-GAAP EPS projected at $0.47 to $0.51
- Full-year 2025 revenue raised to $82.5M–$83.5M
- Full U.S. rollout of next-gen 3870 IV pump planned for Q1 2026
Challenges Ahead
- Free cash flow declined compared to prior year due to facility costs
- Cash from operations decreased to $7.0M from $9.1M year-over-year
- Higher inventory and prepaid expenses pressured short-term cash flow
- Some transitional inefficiencies from new facility early in Q3
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...